These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 21996585)
1. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585 [TBL] [Abstract][Full Text] [Related]
2. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061 [TBL] [Abstract][Full Text] [Related]
3. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874 [TBL] [Abstract][Full Text] [Related]
4. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081 [TBL] [Abstract][Full Text] [Related]
5. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y Digestion; 2014; 89(1):12-7. PubMed ID: 24458107 [TBL] [Abstract][Full Text] [Related]
6. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
7. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754 [TBL] [Abstract][Full Text] [Related]
8. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022 [TBL] [Abstract][Full Text] [Related]
9. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439 [TBL] [Abstract][Full Text] [Related]
11. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154 [TBL] [Abstract][Full Text] [Related]
12. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325 [TBL] [Abstract][Full Text] [Related]
13. Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. Goltsov A; Faratian D; Langdon SP; Bown J; Goryanin I; Harrison DJ Cell Signal; 2011 Feb; 23(2):407-16. PubMed ID: 20951800 [TBL] [Abstract][Full Text] [Related]
14. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Araki K; Miyoshi Y Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897 [TBL] [Abstract][Full Text] [Related]
18. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379 [TBL] [Abstract][Full Text] [Related]
19. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585 [TBL] [Abstract][Full Text] [Related]
20. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1. Berglund FM; Weerasinghe NR; Davidson L; Lim JC; Eickholt BJ; Leslie NR Oncogene; 2013 Sep; 32(37):4417-26. PubMed ID: 23085752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]